Korean J Ophthalmol.  2007 Mar;21(1):11-17. 10.3341/kjo.2007.21.1.11.

Laser Photocoagulation Combined with Intravitreal Triamcinolone Acetonide Injection in Proliferative Diabetic Retinopathy with Macular Edema

• Choi KS
• Chung JK
• Lim SH

• KMID: 1105024
• DOI: http://doi.org/10.3341/kjo.2007.21.1.11

Abstract

PURPOSE: To evaluate therapeutic effects and usefulness of a combination treatment of intravitreal injection of triamcinolone acetonide (IVTA) and panretinal photocoagulation (PRP) in patients with clinically significant macular edema secondary to proliferative diabetic retinopathy (PDR). METHODS: Visual acuity test, fundoscopy, fluorescein angiography, and optical coherence tomography (OCT) were taken in 20 patients (20 eyes) of macular edema and PDR. A combination of intravitreal injection of triamcinolone acetonide and PRP was performed in 10 patients (10 eyes) and a combination of focal or grid laser photocoaqulation and PRP in the remaining 10 eyes. The postoperative outcomes were compared between the two combination treatments by best corrected visual acuity (BCVA), tonometry, fluorescein angiography, and OCT at 2 weeks, 1, 2, and 3 months. RESULTS: Average BCVA (log MAR) significantly improved from preoperative 0.56+/-0.20 to 0.43+/-0.08 at 1 month (P=0.042) and it was maintained until 3 months after a combination of IVTA and PRP in 10 eyes (P=0.007). The thickness of fovea decreased from average 433.3+/-114.9 micrometer to average 279.5+/-34.1 micrometer at 2 weeks after combined treatment of IVTA and PRP (P=0.005), which was significantly maintained until 3 months, but there was a transient visual disturbance and no significant difference in thickness of the fovea before and after treatment in the groups with PRP and focal or grid laser photocoagulation. CONCLUSIONS: A combination of IVTA and PRP might be an effective treatment modality in the treatment of macular edema and PDR and prevent the subsequent PRP-induced macular edema result in visual dysfunction. In combination with PRP, IVTA might be more effective than focal or grid laser photocoagulation and PRP for reducing diabetic macular edema and preventing aggravation of macular edema without transient visual disturbance in patients requiring immediate PRP.

Keyword

Intravitreal triamcinolone acetonide injection; Macular edema; Panretinal photocoagulation; Proliferative diabetic retinopathy

MeSH Terms

Vitreous Body
Triamcinolone Acetonide/*administration & dosage/therapeutic use
Treatment Outcome
Middle Aged
Macular Edema, Cystoid/*drug therapy/etiology/*surgery
*Laser Coagulation
Injections
Humans
Glucocorticoids/*administration & dosage/therapeutic use
Diabetic Retinopathy/*complications
Aged

Figure

• 

  Fig. 1 Evaluation of mean foveal thickness and best corrected visual acuity after combined intravitreal injection of triamcinolone acetonid and panretinal photocoagulation. ⋆: statistically significant difference between initial foveal thickness and each value, *: statistically significant difference between best corrected visual acuity before and after combination treatment.

• 

  Fig. 2 Changes of foveal thickness and best corrected visual acuity in patients treated with focal or grid laser photocoagulation and panretinal photocoagulation. *: statistically significant difference between best corrected visual acuity before and after laser treatment. The values of foveal thicknessare not significantly different from baseline.

• 

  Fig. 3 Fundus photographs (top), fluorescein angiograms (middle), and optical coherence tomography (bottom) of case 7 in combination treatment group. (A) Findings of initial examination. (B) One month after combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation. Late-phase fluorescein angiogram showing the marked decreased amount of leaking on macula and perivascular area. Note the decreased foveal thickness as seen on the optical coherence tomography.

• 

  Fig. 4 Fundus photographs (top), fluorescein angiograms (middle), and optical coherence tomography (bottom) of case 1 in laser treatment group. (A) Findings of initial examination. (B) One month after grid laser photocoagulation and panretinal photocoagulation. Late-phase fluorescein angiogram showing increased amount of fluid collection on macula. Note the increased foveal thickness as seen on the optical coherence tomography in spite of laser treatment.

Reference

1. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003; 136:122–135. PMID: 12834680.

2. Akduman L, Olk RJ. Laser photocoagulation of diabetic macular edema. Ophthalmic Surg Lasers. 1997; 28:387–408. PMID: 9150523.

3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103:1796–1806. PMID: 2866759.

4. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987; 94:761–774. PMID: 3658348.

5. Ferris FL, Podgor MJ, Davis MD. Macular edema in diabetic retinopathy study patients Diabetic Retinopathy Study Group report number 12. Ophthalmology. 1987; 94:754–760. PMID: 3658347.

6. Kleiner RC, Elman MJ, Murphy RP, Ferris FL 3rd. Transient severe visual loss after panretinal photocoagulation. Am J Ophthalmol. 1988; 106:298–306. PMID: 3421291.

7. Meyers SM. Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol. 1980; 90:210–216. PMID: 6158867.

8. Shimura M, Yasuda K, Nakazaya T, et al. Quantifying alterations of macular thickness before and after pan-retinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology. 2003; 110:2386–2394. PMID: 14644723.

9. Shimura M, Yasuda K, Nakazawa T, Tamai M. Visual Dysfunction After Panretinal Photocoagulation in Patients With Severe Diabetic Retinopathy and Good Vision. Am J Ophthalmol. 2005; 140:8–15. PMID: 15939392.

10. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003; 121:57–61. PMID: 12523885.

11. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Am J Ophthalmol. 2002; 109:920–927.

12. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000; 84:1064–1067. PMID: 10966969.

13. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol. 2002; 240:423–429. PMID: 12107507.

14. Bresnick GH. Diabetic macular edema: a review. Ophthalmology. 1986; 93:989–997. PMID: 3531959.

15. Diabetic Retinopathy Study Research Group. Diabetic Retinopathy Study. Report 6. Design, methods and baseline results. Invest Ophthalmol Vis Sci. 1981; 21:149–209.

16. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001; 44:156–163. PMID: 11270671.

17. McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina. 1985; 5:5–10. PMID: 4001591.

18. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1985; 92:388–393. PMID: 4039432.

19. Higgins KE, Meyers SM, Jaffe MJ, et al. Temporary loss of foveal contrast sensitivity associated with panretinal photocoagulation. Arch Ophthalmol. 1998; 104:997–1003. PMID: 3729795.

20. Gardner TW, Eller AW, Friberg TR. Reduction of severe macular edema in eyes with poor vision after panretinal photocoagulation for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1991; 229:323–328. PMID: 1916318.

21. Aiello LM. Albert DM, Jakobiec FA, editors. Diagnosis, management and treatment of nonproliferative diabetic retinopathy and macular edema. Principles and Practice of Ophthalmology. 2000. v. 3:2nd ed. Philadelphia: WB Saunders;chap. 138.

22. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991; 98:766–786. PMID: 2062512.

23. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003; 87:24–27. PMID: 12488256.

24. Jonas JB, Kreissig I, Degenring R. Secondary chronic open angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol. 2003; 121:729–730. PMID: 12742856.

25. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003; 136:791–796. PMID: 14597028.

26. Antoszyk AN, Gottlieb JL, Machemer R, Hatchel DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefe Arch Clin Exp Ophthalmol. 1993; 231:34–40.

27. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003; 121:667–673. PMID: 12742844.

28. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Regression of neovascular iris vessel by intravitreal injection of crystalline cortisol. J Glaucoma. 2001; 10:284–287. PMID: 11558812.

29. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110:1155–1159. PMID: 1497531.

30. Zacks DN, Johnson MW. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina. 2005; 25:135–140. PMID: 15689801.